Updated:
South Texas Research Institute
The South Texas Research Institute functions as a multi-therapeutic clinical trial site headquartered in South Texas, with a principal focus on...
South Texas Research Institute
The South Texas Research Institute functions as a multi-therapeutic clinical trial site headquartered in South Texas, with a principal focus on cardiometabolic indications including type 2 diabetes, dyslipidemia, and non-alcoholic steatohepatitis. The organization recruits from a predominantly Hispanic patient base spanning the Lower Rio Grande Valley, a demographic disproportionately affected by metabolic disease and historically underrepresented in registrational trials — a pairing that has attracted trial placements from sponsors including Novo Nordisk, Eli Lilly, and Boehringer Ingelheim. The institute's model centers on dedicated research facilities rather than a hospital-based or academic medical center structure, operating as an independent network of clinical trial sites that can scale enrollment across multiple locations in the region. The site has conducted studies for GLP-1 receptor agonists, SGLT2 inhibitors, and NASH therapeutics, leveraging a combination of full-time principal investigators, sub-investigators, and bilingual study coordinators trained in ICH-GCP guidelines. The geographic concentration in the Rio Grande Valley provides access to a largely treatment-naïve patient pool with high prevalence of the target conditions. Leadership, staffing levels, and total trial portfolio volume are not publicly detailed. The organization does not maintain a public-facing website with institutional history or a LinkedIn presence as of mid-2026. Sponsors typically engage the institute through clinical trial registries, CRO-mediated feasibility assessments, and investigator-brochure databases rather than through direct institutional marketing channels. Structurally, the institute represents a site-level consolidator play in the fragmented US clinical trial infrastructure — a model where dedicated research sites in underrepresented geographic and demographic corridors serve as preferred enrollment venues for global pharmaceutical programs seeking regulatory-grade diversity data. The long-term viability of the model depends on continued sponsor demand for Hispanic metabolic trial cohorts and the institute's ability to maintain principal investigator continuity across successive study awards.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
—
Corporate office
United States
Frequently asked questions
What therapeutic areas does South Texas Research Institute specialize in?
The institute concentrates on cardiovascular and metabolic indications — type 2 diabetes, dyslipidemia, non-alcoholic steatohepatitis (NASH), and obesity — reflecting the disease burden of its predominantly Hispanic patient base in the Rio Grande Valley. Trial listings reviewed by industry databases confirm participation in studies for GLP-1 receptor agonists and SGLT2 inhibitors.
Why do pharmaceutical sponsors select this site over other US clinical trial locations?
Sponsors pursuing regulatory approval with diversity requirements value the institute's access to a largely Hispanic, treatment-naïve population with high metabolic disease prevalence — a demographic the FDA explicitly encourages in enrollment plans. The site's independent structure can also offer faster startup timelines than academic medical centers.
Is South Texas Research Institute a single site or a network?
Public trial records suggest multiple enrolling locations in the Lower Rio Grande Valley, indicating a networked site model rather than a single standalone clinic. The exact number of active sites or affiliate locations is not disclosed in publicly available documents.
Does the institute operate as an academic center or a private entity?
It functions as an independent, non-academic contract research site — no university affiliation is evident in trial registrations, investigator profiles, or available corporate records. This places it in the category of dedicated clinical trial sites rather than investigator-initiated academic research units.
Who are the principal investigators leading trials at the institute?
Individual investigator names have appeared on ClinicalTrials.gov listings for studies executed through the South Texas Research Institute, but identifying a consistent lead PI or ownership principal from public records is not currently possible. Industry-standard site-selection databases that require subscription access typically carry this detail.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: